404 related articles for article (PubMed ID: 17489964)
1. Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas.
Bahra M; Jacob D; Pascher A; Plockinger U; Kristiansen G; Neuhaus P; Langrehr JM
J Gastroenterol Hepatol; 2007 Jun; 22(6):930-5. PubMed ID: 17489964
[TBL] [Abstract][Full Text] [Related]
2. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
3. Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas.
Matthews BD; Heniford BT; Reardon PR; Brunicardi FC; Greene FL
Am Surg; 2000 Dec; 66(12):1116-22; discussion 1122-3. PubMed ID: 11149582
[TBL] [Abstract][Full Text] [Related]
4. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?
Teh SH; Deveney C; Sheppard BC
Am J Surg; 2007 May; 193(5):610-3; discussion 613. PubMed ID: 17434366
[TBL] [Abstract][Full Text] [Related]
5. Resection of pancreatic neuroendocrine tumors: results of 70 cases.
Kazanjian KK; Reber HA; Hines OJ
Arch Surg; 2006 Aug; 141(8):765-9; discussion 769-70. PubMed ID: 16924083
[TBL] [Abstract][Full Text] [Related]
6. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
Ridwelski K; Meyer F; Schmidt U; Lippert H
Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961
[TBL] [Abstract][Full Text] [Related]
7. Surgical treatment of intraductal papillary-mucinous tumors of the pancreas.
Kanazumi N; Nakao A; Kaneko T; Takeda S; Harada A; Inoue S; Nagasaka T; Nakashima N
Hepatogastroenterology; 2001; 48(40):967-71. PubMed ID: 11490850
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic head resection with segmental duodenectomy: safety and long-term results.
Nakao A; Fernández-Cruz L
Ann Surg; 2007 Dec; 246(6):923-8; discussion 929-31. PubMed ID: 18043093
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G
Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345
[TBL] [Abstract][Full Text] [Related]
10. [Operative management and long-term survival in patients with neuroendocrine tumors of the pancreas--experience with 144 patients].
Fendrich V; Habbe N; Celik I; Langer P; Zielke A; Bartsch DK; Rothmund M
Dtsch Med Wochenschr; 2007 Feb; 132(5):195-200. PubMed ID: 17252361
[TBL] [Abstract][Full Text] [Related]
11. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.
Bilimoria KY; Talamonti MS; Tomlinson JS; Stewart AK; Winchester DP; Ko CY; Bentrem DJ
Ann Surg; 2008 Mar; 247(3):490-500. PubMed ID: 18376195
[TBL] [Abstract][Full Text] [Related]
12. [Surgical effect of malignant tumor of body and tail of the pancreas: compare with pancreatic head cancer].
Wu TC; Shao YF; Shan Y; Wu JX; Zhao P
Zhonghua Wai Ke Za Zhi; 2007 Jan; 45(1):30-3. PubMed ID: 17403286
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment.
Jarufe NP; Coldham C; Orug T; Mayer AD; Mirza DF; Buckels JA; Bramhall SR
Dig Surg; 2005; 22(3):157-62. PubMed ID: 16043962
[TBL] [Abstract][Full Text] [Related]
14. [Management of nonfunctioning islet cell tumors of the pancreas].
Liang H; Wang XN; Wang BG; Pan Y; Ding XW; Hao XS
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):457-60. PubMed ID: 17974283
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas.
Fischer L; Kleeff J; Esposito I; Hinz U; Zimmermann A; Friess H; Büchler MW
Br J Surg; 2008 May; 95(5):627-35. PubMed ID: 18306152
[TBL] [Abstract][Full Text] [Related]
16. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
[TBL] [Abstract][Full Text] [Related]
17. Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas: long-term survival analysis.
Sarmiento JM; Farnell MB; Que FG; Nagorney DM
World J Surg; 2002 Oct; 26(10):1267-71. PubMed ID: 12205558
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.
Hill JS; McPhee JT; McDade TP; Zhou Z; Sullivan ME; Whalen GF; Tseng JF
Cancer; 2009 Feb; 115(4):741-51. PubMed ID: 19130464
[TBL] [Abstract][Full Text] [Related]
19. Surgical treatment of neuroendocrine tumors of the lung.
Daddi N; Ferolla P; Urbani M; Semeraro A; Avenia N; Ribacchi R; Puma F; Daddi G
Eur J Cardiothorac Surg; 2004 Oct; 26(4):813-7. PubMed ID: 15450578
[TBL] [Abstract][Full Text] [Related]
20. Middle segmental pancreatic resection: An option to treat benign pancreatic body lesions.
Müller MW; Friess H; Kleeff J; Hinz U; Wente MN; Paramythiotis D; Berberat PO; Ceyhan GO; Büchler MW
Ann Surg; 2006 Dec; 244(6):909-18; discussion 918-20. PubMed ID: 17122616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
